[{"NetIncomeLoss_1_Q3_USD":-52390.0,"SaleOfStockConsiderationReceivedPerTransaction_1_Q3_USD":10000.0,"AssetsCurrent_0_Q3_USD":1621846.0,"NetCashProvidedByUsedInInvestingActivities_1_Q3_USD":-166750000.0,"AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_1_Q3_USD":-9624742.0,"AccruedLiabilitiesCurrent_0_Q3_USD":74394.0,"CommitmentsAndContingencies_0_Q3_USD":null,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":16675000.0,"GeneralAndAdministrativeExpense_1_Q3_USD":18759.0,"PreferredStockSharesOutstanding_0_Q3_shares":null,"ProceedsFromRelatedPartyDebt_1_Q3_USD":25.0,"Liabilities_0_Q3_USD":5951300.0,"Cash_0_Q3_USD":1600000.0,"AdditionalPaidInCapitalCommonStock_0_Q3_USD":5052305.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":1552227.0,"IncreaseDecreaseInAccountsPayable_1_Q3_USD":5165.0,"SharesIssuedPricePerShare_0_Q3_USD":10.0,"PaymentsOfStockIssuanceCosts_1_Q3_USD":3591285.0,"TemporaryEquityShareSubscriptions_0_Q3_shares":15743239.0,"StockIssuedDuringPeriodValueOther_1_Q3_USD":166750000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q3_USD":168391508.0,"ProceedsFromIssuanceOfPrivatePlacement_1_Q3_USD":5335000.0,"StockIssuedDuringPeriodSharesIssuedForServices_1_Q3_shares":25000000.0,"CashAndCashEquivalentsPeriodIncreaseDecrease_1_Q3_USD":1552227.0,"CommonStockValue_0_Q3_USD":563.0,"IncreaseDecreaseInAccruedLiabilities_1_Q3_USD":4394.0,"TemporaryEquityCarryingAmountAttributableToParent_0_Q3_USD":157432390.0,"ProceedsFromRepaymentsOfRelatedPartyDebt_1_Q3_USD":-127232.0,"AssetsHeldInTrust_0_Q3_USD":166761850.0,"SaleOfStockPricePerShare_0_Q3_USD":10.0,"PreferredStockSharesIssued_0_Q3_shares":null,"RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_1_Q3_USD":10000.0,"AccountsPayableCurrent_0_Q3_USD":5165.0,"LiabilitiesCurrent_0_Q3_USD":115050.0,"NetCashProvidedByUsedInOperatingActivities_1_Q3_USD":-89281.0,"CommonStockSharesOutstanding_0_Q3_shares":5634011.0,"DebtInstrumentConvertibleConversionPrice1_0_Q3_USD":10.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-52862.0,"StockholdersEquity_0_Q3_USD":5000006.0,"DebtInstrumentUnusedBorrowingCapacityFee_1_Q3_USD":127000.0,"EarningsPerShareBasicAndDiluted_1_Q3_USD":0.0,"SharePrice_0_Q3_USD":0.35,"PrepaidExpenseCurrent_0_Q3_USD":69619.0,"PreferredStockSharesAuthorized_0_Q3_shares":1000000.0,"PreferredStockValue_0_Q3_USD":null,"BusinessCombinationConsiderationTransferred1_1_Q3_USD":1500000.0,"InvestmentIncomeInterest_1_Q3_USD":11860.0,"ProceedsFromIssuanceInitialPublicOffering_1_Q3_USD":166750000.0,"OperatingIncomeLoss_1_Q3_USD":-64250.0,"CommonStockSharesAuthorized_0_Q3_shares":30000000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"ProceedsFromIssuanceOfCommonStock_1_Q3_USD":25000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"StockRedeemedOrCalledDuringPeriodValue_1_Q3_USD":-157432390.0,"Assets_0_Q3_USD":168383696.0,"CommonStockSharesIssued_0_Q3_shares":5634011.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":168383696.0,"IncreaseDecreaseInPrepaidExpense_1_Q3_USD":69619.0,"Ticker":"TNGX","CIK":"1819133","name":"BCTG ACQUISITION CORP.","OfficialName":"Tango Therapeutics Inc.","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"650767383.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201113"}]